Angelina Pharma To Buy Catalyst For $4.1B; Catalyst Also Settles FIRDAPSE Patent Litigation
Angelini Pharma has agreed to acquire Catalyst Pharmaceuticals Inc. (CPRX) for $31.50 per share in cash, valuing the company at approximately $4.1 billion (3.5 billion euros). The Board of Directors of both companies has unanimously approved the …